DUB1 Activators
USP36, a member of the ubiquitin-specific protease family, functions as a cysteine protease involved in deubiquitinating polyubiquitinated proteins. Its known role includes the deubiquitination and stabilization of the transcription factor c-Myc, a crucial oncoprotein upregulated in various human cancers. Additionally, USP36 is implicated in the regulation of autophagy, adding another layer of complexity to its cellular functions. Elevated expression of USP36 is observed in certain breast and lung cancers, emphasizing its potential significance in tumorigenesis.
Activation of USP36 involves a dynamic interplay with various chemical modulators targeting specific cellular pathways. Direct activators like Nutlin-3 and MLN4924 impact c-Myc stabilization by disrupting its ubiquitin-proteasome pathway and neddylation, respectively. Indirect activators, such as Rapamycin and Chloroquine, influence autophagy, indirectly up-regulating USP36 by modulating cellular processes. Compounds like JQ1 and C646 indirectly affect USP36 by interfering with bromodomain or histone acetylation, influencing c-Myc expression and stability. The activation of USP36 is intricately linked to the regulation of c-Myc and autophagy, highlighting its role in maintaining protein homeostasis and cellular processes crucial for cancer development. Understanding the diverse mechanisms of USP36 activation provides insights into its potential as a target and the intricate network of pathways it modulates in cancer biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $122.00 $219.00 | 2 | |
Nutlin-3, a direct activator, enhances USP36 by stabilizing c-Myc. It disrupts the interaction between c-Myc and its E3 ubiquitin ligase, preventing ubiquitination and degradation. This leads to increased levels of c-Myc, promoting USP36 stabilization. Nutlin-3's role in disrupting the ubiquitin-proteasome pathway directly supports the activation of USP36, influencing the dynamics of c-Myc regulation and contributing to the protease's up-regulation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a bromodomain inhibitor, indirectly activates USP36 by inhibiting BET proteins. This disruption impacts c-Myc expression and stability, indirectly up-regulating USP36. JQ1's action on the bromodomain interferes with the transcriptional regulation of c-Myc, influencing the protease's activation. The compound's indirect modulation of USP36 through BET protein inhibition provides a unique avenue for enhancing the stability of the target protein. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924, a NEDD8-activating enzyme inhibitor, directly up-regulates USP36 by preventing its neddylation. This inhibition stabilizes the protease, influencing its deubiquitination activity on c-Myc. MLN4924's impact on neddylation pathways provides a specific mechanism for promoting USP36 function, highlighting its role in the regulation of c-Myc and contributing to the protease's activation in cellular contexts. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly activates USP36 by influencing autophagy. By inhibiting mTOR, Rapamycin induces autophagy activation, which, in turn, positively regulates USP36. The compound's action on the mTOR pathway indirectly supports the activation of USP36, suggesting a link between autophagy regulation and the stability of the protease. Rapamycin provides a unique avenue for modulating USP36 through the intricate dynamics of autophagic processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, directly up-regulates USP36 by preventing its degradation. By inhibiting the proteasome, Bortezomib stabilizes the protease, impacting its deubiquitination activity on c-Myc. This direct modulation of the ubiquitin-proteasome pathway promotes USP36 function, highlighting its role in preventing c-Myc degradation and contributing to the protease's activation in cellular contexts. Bortezomib provides a specific avenue for enhancing USP36 stability. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine indirectly activates USP36 by promoting autophagy. By inhibiting lysosomal function, Chloroquine disrupts autophagic flux, influencing c-Myc degradation and indirectly up-regulating USP36. The compound's impact on lysosomal pathways provides a specific mechanism for modulating USP36 through the intricate dynamics of autophagic processes. Chloroquine offers a unique avenue for promoting the stability of USP36 and influencing its role in c-Myc regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, directly up-regulates USP36 by preventing its degradation. By inhibiting the proteasome, MG-132 stabilizes the protease, impacting its deubiquitination activity on c-Myc. This direct modulation of the ubiquitin-proteasome pathway promotes USP36 function, preventing c-Myc degradation and contributing to the protease's activation in cellular contexts. MG-132 provides a specific avenue for enhancing USP36 stability. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3-kinase inhibitor, indirectly activates USP36 by influencing autophagy. By inhibiting PI3-kinase, Wortmannin induces autophagy activation, which positively regulates USP36. The compound's action on the PI3-kinase pathway indirectly supports the activation of USP36, suggesting a link between autophagy regulation and the stability of the protease. Wortmannin provides a unique avenue for modulating USP36 through the intricate dynamics of autophagic processes. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646, a histone acetyltransferase (HAT) inhibitor, indirectly activates USP36 by impacting c-Myc acetylation. By inhibiting HAT, C646 influences the acetylation status of c-Myc, indirectly up-regulating USP36. The compound's action on histone acetylation provides a specific mechanism for modulating USP36 through the intricate dynamics of c-Myc regulation. C646 offers a unique avenue for promoting the stability of USP36 and influencing its role in c-Myc deubiquitination. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662, an AMPK activator, indirectly activates USP36 by influencing autophagy. By activating AMPK, A769662 induces autophagy activation, which positively regulates USP36. The compound's action on AMPK provides a specific mechanism for modulating USP36 through the intricate dynamics of autophagic processes. A769662 offers a unique avenue for promoting the stability of USP36 and influencing its role in autophagy regulation. | ||||||